Central and Southern Asia vs United Kingdom: Proportion of the target population who received the final dose
Central and Southern Asia
10.0%
in 2024
United Kingdom
75.0%
in 2024
Central and Southern Asia rank
29th
United Kingdom rank
32nd
Proportion of the target population who received the final dose over time
- Central and Southern Asia
- United Kingdom
How they compare
United Kingdom currently reports 75.0% against 10.0% in Central and Southern Asia, a difference of 65.0%.
That makes United Kingdom's figure about 7.5 times Central and Southern Asia's.
Across all 15 years both countries report, United Kingdom has been ahead every year.
Central and Southern Asia ranks 29th and United Kingdom ranks 32nd of 34 groups.
United Kingdom has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Central and Southern Asia | United Kingdom | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.2% | 83.8% | 83.6% | United Kingdom |
| 2020s | 4.0% | 69.2% | 65.2% | United Kingdom |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received the final dose of, Central and Southern Asia or United Kingdom?
- United Kingdom, at 75.0% against 10.0% in Central and Southern Asia as of 2024.
- What is the difference in proportion of the target population who received the final dose of between Central and Southern Asia and United Kingdom?
- 65.0%, with United Kingdom ahead.
- How many years of comparable data are there for Central and Southern Asia and United Kingdom?
- 15 years are reported by both, from 2010 to 2024.
- How do Central and Southern Asia and United Kingdom rank globally for proportion of the target population who received the final dose of?
- Central and Southern Asia ranks 29th and United Kingdom ranks 32nd of 34 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received the final dose of human papillomavirus (HPV) vaccine (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.